Arrowhead Pharmaceuticals Inc.
Sector: Manufacturing
Industry: Pharmaceutical Products
13.97
0.94
(7.21%)
Volume:
2,097,414
52 week range:
9.57 - 30.41
Market Cap:
1.643B
Company Description:
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the. treatment of liver diseases associated with alpha-1 antitrypsin deficiency. ARO is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A.